Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1617-1625
DOI: 10.1111/apt.70612 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 31.03.2026. Verfasst von Rong Ding und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Yunnan Science and Technology Talent and Platform Program, Jiangsu Provincial Basic Research Program Natural Science Foundation-Frontier Leading Technology Basic Research Project.
Abstract (Originalsprache)
Background
This real‐world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone.
Methods
In this nationwide, multi‐centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T‐C‐A) or camrelizumab and apatinib alone (C‐A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression‐free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety.
Results
A total of 252 HCC patients were included (T‐C‐A group, n = 183; C‐A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T‐C‐A group compared to the C‐A group (24.2 months [95% CI: 21.4–33.4] vs. 15.2 months [95% CI: 9.8–21.0]; p < 0.001). The T‐C‐A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8–12.2], compared to 4.9 months [95% CI: 4.0–12.5] in the C‐A group ( p < 0.001). Further, the ORR was higher in the T‐C‐A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T‐C‐A group and 14.5% in the C‐A group.
Conclusion
The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
- Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
- Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.
- Department of Radiology, The Second Xiangya Hospital of Central South University, Hunan, China.
- Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, China.
- Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
ORCID-Profile: Jin-Feng Bai, Zhi-Cheng Jin, Yu-Jing Xin, Hai-Bin Shi, Fanpu Ji, Jian-Song Ji, Hai-Dong Zhu, Zheng-Gang Ren, Gao-Jun Teng
Förderung
- National Natural Science Foundation of China
- Yunnan Science and Technology Talent and Platform Program
- Jiangsu Provincial Basic Research Program Natural Science Foundation-Frontier Leading Technology Basic Research Project
- Jiangsu Provincial Collaborative Innovation in Medical-Education-Research-Industry Integration
- China Postdoctoral Science Foundation
- Postdoctoral Fellowship Program of CPSF
- Natural Science Foundation of Jiangsu Province
- National Key Research and Development Program of China
Zitieren
APA
Ding, R., Bai, J. F., Jin, Z. C., Xiao, Y. D., Chen, J. J., Zhu, X. L., Xin, Y. J., Chen, J. Z., Tie, J., Zhu, K. S., Zhang, L., Shi, H. B., Liu, R. B., Xu, A. B., Ji, F., Huang, M. S., Ji, J. S., Yuan, C. W., Yang, W. Z., …, & Teng, G. J. (2026). Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 63(12), 1617-1625. https://doi.org/10.1111/apt.70612
Vancouver
Ding R, Bai JF, Jin ZC, Xiao YD, Chen JJ, Zhu XL, et al. Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2026;63(12):1617-1625. doi:10.1111/apt.70612
BibTeX
@article{Ding2026,
author = {Ding, Rong and Bai, Jin-Feng and Jin, Zhi-Cheng and Xiao, Yu-Dong and Chen, Jian-Jian and Zhu, Xiao-Li and Xin, Yu-Jing and Chen, Jin-Zhang and Tie, Jun and Zhu, Kang-Shun and Zhang, Lan and Shi, Hai-Bin and Liu, Rui-Bao and Xu, Ai-Bing and Ji, Fanpu and Huang, Ming-Sheng and Ji, Jian-Song and Yuan, Chun-Wang and Yang, Wei-Zhu and Xu, Guo-Hui and Tu, Qiang and Jiang, Hua and Shao, Hai-Bo and Shi, Bao-Qi and Huang, Ming and Zhong, Bin-Yan and Zhu, Hai-Dong and Ren, Zheng-Gang and Teng, Gao-Jun},
title = {Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {12},
pages = {1617--1625},
doi = {10.1111/apt.70612}
}
EUVIMED